In a double-blind crossover study the symptomatic and metabolic effects of propranolol, acebutolol, and atenolol were studied during insulin-induced hypoglycaemia in diabetics treated with diet or hypoglycaemic tablets. All the drugs prevented tachycardia, but did not affect the other symptoms of hypoglycaemia. Propranolol delayed the recovery of the blood glucose concentration and impaired the secondary rise in the concentrations of blood lactate and non-esterified fatty acids in diet-treated diabetics. Acebutolol potentiated the hypoglycaemic effect of insulin in tablet-treated diabetics (mean difference of blood glucose concentration 0 7 mmol/l (12 6 mg/100 ml)) and this difference was maintained during the recovery phase4 the blood lactate response was also impaired. Atenolol did not differ perceptibly from placebo in its effects on the metabolic responses to acute hypoglycaemia.
Introduction
Beta-adrenoreceptor blocking drugs may produce troublesome hypoglycaemic side effects in diabetic patients.' The nonselective drugs such as propranolol may potentiate hypoglycaemia and delay the recovery of blood glucose concentrations.1-3 Recent studies have, however, indicated that the cardioselective drugs may not increase the risk of hypoglycaemia. In normal subjects atenolol (Tenormin) does not potentiate hypoglycaemia or delay blood glucose recovery4; and acebutolol (Sectral), although potentiating initial hypoglycaemia, does not prevent blood glucose recovery.,5 The findings with metoprolol (Lopressor) have proved inconclusive, but one report showed that it had no adverse effects on blood glucose concentrations. 3 These findings suggest that the cardioselective drugs might be safer for use in diabetic patients. 6 Unfortunately, this hypothesis is based on findings in normal subjects, which are not strictly applicable to diabetics. We therefore performed a study to test the hypothesis by determining the effects of atenolol and acebutolol during insulin-induced hypoglycaemia in otherwise healthy diabetics. A double-blind crossover study was performed in 12 diabetics. Six were treated on diet alone and six treated with glibenclamide 5-20 mg daily (one also had metformin). There were 10 men and two women, with a mean age of 46 years (15-56). All subjects were normotensive, with normal resting and exercise electrocardiograms and no evidence of diabetic retinopathy. During the study they adhered to their usual treatment and avoided prolonged exercise.
Patients taking hypoglycaemic tablets underwent three episodes of insulin-induced hypoglycaemia at roughly weekly intervals. For 48 hours before each test they took either (a) acebutolol 200 mg twice a day, (b) atenolol 50 mg twice a day, or (c) placebo twice a day, with a After the 150-minute sample all subjects performed a standardised exercise test equal to walking at 1-5 km/hour for three minutes. The pulse rates were noted before and after exercise.
The blood glucose concentrations were estimated using the GODPerid method and the blood lactate concentrations with a lactate dehydrogenase method (Boehringer packs). The blood non-esterified fatty acid concentrations were estimated using a modified Dole titremeteric assay.7 Paired Student's t test was used for statistical analysis.
Results
Pulse rates, exercise tachycardia, and symptoms-Atenolol and propranolol reduced the resting pulse rates, and all drugs partly suppressed exercise-induced tachycardia, which indicated effective beta-adrenoreceptor blockade. In contrast to placebo, atenolol and acebutolol produced no increase of pulse rate during the tests and propranolol caused a sinus bradycardia (table I) . Throughout the hypoglycaemia subjects taking atenolol had lower pulse rates than those taking acebutolol. Palpitation, sweating, and dizziness were not significantly affected by the drugs, although, as expected from the abolition of tachycardia, palpitation during hypoglycaemia was less prominent.
Blood glucose concentrations -The fasting blood glucose concentrations were higher in patients treated with hypoglycaemic drugs than in the diet-treated subjects (see figure) . None of the betablockers produced any significant lowering of fasting blood glucose levels. Maximum hypoglycaemia occurred at 60 minutes in both groups and was equal to a mean fall in blood glucose of 69 % in the diet-treated subjects and 75 % in the drug-treated subjects (expressed as a percentage of the fasting blood glucose concentration). Neither atenolol or acebutolol potentiated the hypoglycaemic effect of insulin in diet-treated subjects, but propranolol significantly reduced the incremental area of the recovery curve. Acebutolol potentiated the hypoglycaemic effect of insulin in tablet-treated subjects, with a fall in mean blood glucose concentrations of 81 % at 60 minutes (P < 0 01) and the concentration was also significantly lower than the control value at 90 and 150 minutes. Nevertheless, the incremental area of the blood glucose recovery curve was identical to that for placebo and atenolol. The mean blood glucose recovery curve on atenolol was similar to that for placebo in both groups of patients.
Blood lactate conzcetrationis-Thc mean fasting blood lactatc concentrations were higher in patients taking hypoglycaemic tablets (table II) . None of the drugs produced any significant fall in fasting blood lactate concentrations. During hypoglycaemia the control mean blood lactate concentration rose by 76 "O at 90 minutes in diet-treated subjects and by 67",, in tablct-treated subjects. Acebutolol impaired this blood lactate response in tablet-treated subjects (P < 0 05) with a rise of only 33 ", at 90 minutes. Propranolol slightly reduced the inc-emental area of blood lactate response in diet-treated subjects (P < 005). Atenolol had no significant effects on blood lactatc concentrations in either group.
Blood NEFA conicenitrations-All drugs significantly lowered fasting blood NEFA concentrations in diet-treated subjects, and acebutolol also lovered them in drug-treated subjects (table III) . After intravenous insulin administration the blood NEFA concentrations fell in all groups. The placebo blood NEFA concentration fell by 56",, at 30 minutes in drug-treated subjects, and by 52",, at 30 minutes in diettreated subjects. The secondary rise of blood NEFA concentrations from adrenaline-mediated lipolysis was reduced in acebutolol-and propranolol-treated diet-controlled subjects. No significant effects on blood NEFA concentrations were observed in the tablet-treated subjects.
Discussion
The results show that these beta-adrenoreceptor blocking drugs differ in their effects on the metabolic responses during insulin-induced hypoglycaemia, and this probably reflects differences in pharmacological selectivity and ancillary properties. Propranolol delayed glucose recovery, as it does in normal subjects. Acebutolol potentiated the hypoglycaemic action of insulin in drug-treated diabetics in a manner similar to that found in normal subjects. Throughout the recovery phase the mean blood glucose concentration remained on average 0 7 mmol/l (12 6 mg/100 ml) lower when patients were taking acebutolol than when they were taking placebo, the incremental area being identical with that for control and atenolol curves. This implies that the magnitude of the adrenaline-induced glycogenolytic response was unaffected but that acebutolol impaired hepatic glucose output in some other way.
The beta-adrenoreceptors of the liver and skeletal muscle are thought to be predominantly of the beta2 type. Hence the beta2 adrenoreceptor blockade of the non-selective drugs might be expected to antagonise adrenaline-mediated glycogenolysis whereas the beta,-blocking drugs should have no such effect.
Hepatic glycogenolysis may, however, also be stimulated directly by a low blood glucose concentration. Studies on liver preparations and exercising normal subjects have shown that drugs with a membrane-stabilising action inhibit glucose release from the liver in response to a low blood glucose concentration. 9 Thus propranolol, possessing this action, impaired postexercise recovery of the blood glucose, whereas metoprolol, without membrane-stabilising activity had no such effect. Acebutolol also possesses membrane-stabilising activity, which probably accounts for its effect on the blood glucose concentration during induction of hypoglycaemia. Furthermore, it is not entirely devoid of beta2-blocking activity and this may also contribute to the hypoglycaemic effect. In contrast, atenolol, being beta, specific and devoid of a membrane-stabilising action, does not affect the metabolic responses to insulin-induced hypoglycaemia.
These findings therefore support the hypothesis that betaadrenoreceptor blocking drugs which are highly beta, specific and devoid of membrane-stabilising activity should be safer than non-selective drugs when used in diabetic patients at risk of hypoglycaemia. Histological clearing of both epidermis and dermis occurred in three patients, and epidermal clearing alone occurred in two. Photochemotherapy may have a place in the treatment of the early and intermediate stages of mycosis fungoides, and it may also be useful as an adjunct to other forms of treatment in the more advanced stages.
Introduction
Mycosis fungoides is a malignancy of T lymphocytes that predominantly affects the skin. Visceral involvement is not commonly recognised even in later stages, and many patients die of their disease without evidence of systemic disease.
Gilchrest et all reported the efficacy of photochemotherapy with systemic psoralens and long-wave ultraviolet A light (PUVA) in nine patients with mycosis fungoides but confirmed this histologically in only one. Hjortshoj and Schmidt2 reported
